ENSC · Ensysce Biosciences, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company's ability to continue as a going concern. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company's ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company's ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $4.5M | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M | $3.93M | — | — | |
| $12.39M | $10.38M | $7.22M | $7.59M | $19.84M | $4.69M | $4.39M | — | — | |
| $4.78M | $4.93M | $4.72M | $5.36M | $6.91M | $18.71M | — | — | — | |
| $20.49M | — | — | — | — | $18.71M | $1.15M | — | — | |
| $17.16M | $15.31M | $11.94M | $12.95M | $26.75M | $23.4M | $5.54M | $3.33M | $1.56M | |
| -$12.66M | -$10.24M | -$6.73M | -$10.72M | -$24.22M | -$19.87M | -$1.61M | -$3.33M | -$959.24K | |
| — | -202.12% | -129.18% | -480.52% | -959.91% | -562.71% | -41.04% | — | — | |
| $15.99K | $18.77K | $1.29M | $353.95K | $109.53K | $1.3M | $995.5K | — | — | |
| $79.92K | — | — | — | — | — | $719.65K | $4.25M | $3.63M | |
| $37.15K | $64.76K | -$1.26M | $91.91K | $14.41K | -$9.28M | $1.45M | — | — | |
| $915.03K | — | — | — | — | — | $4.56M | -$512.1K | $2.68M | |
| $108.59K | — | — | — | — | — | $244.49K | $555.2K | $553.92K | |
| -$12.62M | -$10.18M | -$7.99M | -$10.63M | -$24.21M | -$29.15M | $4.31M | -$1.07M | $2.12M | |
| — | -200.85% | -153.3% | -476.4% | -959.33% | -825.38% | 109.66% | — | — | |
| — | -$487 | -$74 | -$13.2K | -$35.39K | -$62.19K | -$217.65K | — | — | |
| -$12.62M | -$10.18M | -$7.99M | -$10.63M | -$25.09M | -$29.89M | $56.77K | -$2.87M | -$1.34M | |
| USD/shares | -$2.52 | -$3.98 | -$11.45 | -$70.40 | -$2,091.30 | -$5,335.20 | $0.00 | — | — |
| USD/shares | -$2.52 | -$3.98 | -$11.45 | -$70.40 | -$2,091.30 | -$5,328.00 | $0.00 | — | — |
| shares | — | 2.56M | 697.69K | 150.94K | 12K | 5601.2611 | 4380.2014 | 1839.2481 | 1832.5058 |
| shares | — | 2.56M | 697.69K | 150.94K | 12K | 5601.2508 | 4585.3853 | 1839.2481 | 1832.5058 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2020: $196.36M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 199 similar-size Biotechnology companies (of 534 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| MPAR | $5,066,650 | $3,086,464 | $1,293,238 | $2,006,885 | $2,646,579 |
| TAAPOUD | — | $2,123,567 | $937,282 | $516,498 | $884,620 |